0001040130-24-000048.txt : 20240624 0001040130-24-000048.hdr.sgml : 20240624 20240624080939 ACCESSION NUMBER: 0001040130-24-000048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240624 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240624 DATE AS OF CHANGE: 20240624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PETMED EXPRESS INC CENTRAL INDEX KEY: 0001040130 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 650680967 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28827 FILM NUMBER: 241062155 BUSINESS ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 BUSINESS PHONE: (561) 426-4444 MAIL ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 8-K 1 pets-20240624.htm 8-K pets-20240624
0001040130FALSE00010401302024-06-242024-06-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):  June 24, 2024
PetMed Express, Inc.
(Exact name of registrant as specified in its charter)
Florida
000-28827
65-0680967
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
420 South Congress Avenue, Delray Beach, Florida 33445
(Address of principal executive offices) (Zip Code)
(561) 526-4444
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
PETS
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. o



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director

On June 20, 2024, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Leah A. Solivan to serve as a director of the Company beginning June 24, 2024. Ms. Solivan will hold this position until the 2024 annual meeting of the Company’s shareholders or until her successor is elected and qualified, subject to her earlier resignation or removal. Ms. Solivan will also serve on the Board’s Compensation and Human Capital Committee and Corporate Governance and Nominating Committee. In connection with her appointment to the Board, Ms. Solivan will receive compensation in accordance with the Company’s Non-Employee Director Compensation Program.

Leah Solivan, age 44, is currently a Managing Director at Fuel Capital L.P., a seed stage venture capital firm investing in consumer, software as a service (SaaS) and infrastructure companies, where she manages three high performing funds, with over seven unicorn companies across the portfolio. Ms. Solivan has served at Fuel Capital since July 2017.

Ms. Solivan began her career as a software engineer at IBM and subsequently founded TaskRabbit, Inc. (“TaskRabbit”), a pioneering on-demand marketplace company in 2008. As TaskRabbit’s CEO for eight years, Ms. Solivan raised more than $50 million in venture capital and scaled the company into an international business with operations in 44 cities. In 2017, she oversaw TaskRabbit’s successful sale to Inter IKEA Systems B.V.

Additionally, Ms. Solivan has taken an active role in the Young Presidents’ Organization (“YPO”), a worldwide leadership community of chief executives. A member since 2014, she was awarded the Alexander Capello Award, the highest honor in membership, for her work in promoting gender equity. In 2023 she became Chair of the Regional Board, Pacific US; she also serves on a global committee for the YPO International Board. Ms. Solivan has been recognized by the World Economic Forum as a Young Global Leader. She has served as an advisor to children’s apparel brand Monica + Andy since July of 2017 and as a venture advisor to Screendoor Partners since January 2021.

Ms. Solivan has been a frequent speaker at events such as the World Economic Forum in Davos, Switzerland and Tina Brown’s Women in the World Summit. Her achievements have been featured in publications, including the Wall Street Journal, Wired, and Time, and Fast Company named her one of the “100 Most Creative People in Business.” She is a regular contributor to Fast Company and has appeared on MSNBC and Bloomberg — among other broadcasts.

Ms. Solivan earned a B.S. in Mathematics and Computer Science from Sweet Briar College, where she also served on the Board of Directors from July 2015 until August 2018.

There are no family relationships between Ms. Solivan and any other executive officers or directors of the Company. There is no arrangement or understanding between Ms. Solivan and any other persons pursuant to which she was selected as director. There are no transactions to which the Company is a party and in which Ms. Solivan has a material interest that is required to be disclosed under Item 404(a) of Regulation S-K.

Ms. Solivan and the Company will enter into the Company’s standard form of director indemnification agreement, whereby the Company agrees to indemnify, defend and hold its directors harmless from and against losses and expenses incurred as a result of their Board service, subject to the terms and conditions provided in the agreement. The form of indemnification agreement is filed as Exhibit 10.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, filed with the Securities and Exchange Commission on June 14, 2024.

Item 7.01 Regulation FD Disclosure

On June 24, 2024, the Company issued a press release announcing the appointment of Ms. Solivan as a member of the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 and the related information in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing made by the Company under the Securities Act or the Exchange Act except as set forth by specific reference in such filing.
2

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits
Exhibit No.
Description
99.1
104
Cover Page Interactive Data File (formatted as Inline XBRL)


* * *
3

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 24, 2024
PETMED EXPRESS, INC.
By:/s/ Christine Chambers
Name:Christine Chambers
Title:
Chief Financial Officer, Treasurer and Secretary
4
 EX-99.1 2 pets-20240624xexx991pressr.htm EX-99.1 Document

EXHIBIT 99.1
PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors
Visionary founder and investor brings decades of experience building and scaling digital consumer brands

DELRAY BEACH, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment of Leah Solivan to the Company’s Board of Directors (“the Board”), effective June 24, 2024. Solivan brings over 20 years of experience building and scaling technology businesses to the Company’s Board. As a General Partner at Fuel Capital, she focuses on early-stage investments across a variety of sectors, including consumer technology, hardware, education, marketplaces, and retail. Her entrepreneurial acumen is exemplified by her founding of TaskRabbit in 2008, which she steered through significant growth phases before orchestrating its successful acquisition by IKEA in 2017.

“Leah’s strong digital background and proven track record of scaling technology-driven businesses from startups to billion-dollar enterprises will make her an invaluable advisor and member of our Board. Leah has demonstrated a remarkable ability to launch and grow consumer brands that deeply resonate with their target audiences. Her insights and experience will be instrumental in helping guide our strategic direction and accelerating our growth trajectory,” said Leslie C. G. Campbell, Chairman of the Board. “We are delighted to welcome her to the Board during this transformational period for the Company.”

Sandra Campos, President and CEO, commented, “We are ecstatic to welcome Leah to our Board. Her diverse experience as a consumer-centric, entrepreneurial visionary will be invaluable to our growth. Leah's strategic insight and technology acumen, combined with her passion for pets—including her beloved Maine Coon cat and equestrian pursuits—align perfectly with our commitment to providing exceptional preventive and wellness products for dogs, cats, and horses.”

“I’m excited to join the Board at this pivotal moment in the company’s journey,” said Ms. Solivan. “As the company continues to enhance its technological capabilities and deepen its understanding of consumer needs, we have a tremendous opportunity to expand our position as a trusted go-to leader in our industry. My experience as a pet owner fuels my dedication to our purpose and I’m eager to collaborate with my fellow Board members to drive growth, expand our market presence, and create lasting value for all stakeholders.”

About Leah Solivan

Ms. Solivan is currently a General Partner at Fuel Capital, a seed stage venture capital firm investing in consumer, software as a service (SaaS) and infrastructure companies. Ms. Solivan has served at Fuel Capital since July 2017.

Before Fuel Capital, Ms. Solivan created one of the most widely recognized new consumer technology brands of the past decades with TaskRabbit, the pioneering on-demand marketplace company she founded in 2008. As TaskRabbit’s CEO for eight years, Leah scaled the company into an international business with operations in 44 cities and more than $50 million in venture capital funding. In 2017, Ms. Solivan oversaw TaskRabbit’s successful sale to IKEA, the multinational home decor corporation.

Ms. Solivan began her career as a software engineer at IBM, where she worked for seven years on products including Lotus Notes and Domino.

With over twenty years of experience, Ms. Solivan is a frequent speaker on topics such as entrepreneurship, the future of work, and women in technology. Ms. Solivan’s achievements have been featured in publications including the Wall Street Journal, Wired, and Time, and Fast Company named her one of the “100 Most Creative People in Business.” Ms. Solivan holds a Bachelor of Science degree in Mathematics and Computer Science from Sweet Briar College, where she has served on the Board of Directors.

About PetMed Express, Inc.
Founded in 1996, PetMeds is a leader in the digital pet pharmacy industry. As a national online retailer, PetMeds.com and PetCareRx.com are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth and insurance partnerships, they offer unparalleled value and convenience to pet parents at every stage of their pets' lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, www.PetMeds.com and www.PetCareRx.com.



Forward Looking Statement
This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.


Investor Contact:
ICR, LLC
John Mills
(646) 277-1254

Reed Anderson
(646) 277-1260
investor@petmeds.com

 EX-101.SCH 3 pets-20240624.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pets-20240624_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 pets-20240624_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 24, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 24, 2024
Entity Registrant Name PetMed Express, Inc.
Entity Incorporation, State or Country Code FL
Entity File Number 000-28827
Entity Tax Identification Number 65-0680967
Entity Address, Address Line One 420 South Congress Avenue
Entity Address, City or Town Delray Beach
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33445
City Area Code 561
Local Phone Number 526-4444
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol PETS
Entity Emerging Growth Company false
Entity Central Index Key 0001040130
Amendment Flag false
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.1800petmeds.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pets-20240624.htm pets-20240624.xsd pets-20240624_lab.xml pets-20240624_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pets-20240624.htm": { "nsprefix": "pets", "nsuri": "http://www.1800petmeds.com/20240624", "dts": { "inline": { "local": [ "pets-20240624.htm" ] }, "schema": { "local": [ "pets-20240624.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "pets-20240624_lab.xml" ] }, "presentationLink": { "local": [ "pets-20240624_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://www.1800petmeds.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pets-20240624.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pets-20240624.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.1800petmeds.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001040130-24-000048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001040130-24-000048-xbrl.zip M4$L#!!0 ( #-!V%AW$E4L\A4 /J$ 1 <&5TV-@&$B"7?0BA':;-94/F=/9\.8^P!7AJ+(]D M)S"_?M]7DLTE)($V;4C;?69G I:E5^_])G'XS\DX(C=,R)#'1Z]XY3*8>Q3&GLLWS\ MG9D7A^/C/I7Y\/MA0&CS.S M7"^?)&"S+:@).??OKI, W3B!TG+)46LJRSYU4/R_K+ MP[*>NL^#Z?%A$-X0F4XC=E0*0IE$=-J,>

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pets-20240624_htm.xml IDEA: XBRL DOCUMENT 0001040130 2024-06-24 2024-06-24 0001040130 false 8-K 2024-06-24 PetMed Express, Inc. FL 000-28827 65-0680967 420 South Congress Avenue Delray Beach FL 33445 561 526-4444 false false false false Common Stock, par value $.001 per share PETS NASDAQ false